Does TRICARE Cover Addyi (Flibanserin)?

What Is Flibanserin (Addyi) and Why Does It Need Special Approval?

Flibanserin is the only FDA-approved non-hormonal oral treatment for acquired, generalized HSDD in premenopausal women. The FDA granted approval on August 18, 2015, under a Risk Evaluation and Mitigation Strategy (REMS) program because of a clinically significant hypotension and syncope risk when the drug is combined with alcohol or certain CYP3A4 inhibitors. Prescribers and pharmacies must both be certified under that REMS program.

The Mechanism Behind the Drug

Flibanserin acts as a serotonin 1A agonist and serotonin 2A antagonist, with additional dopamine D4 agonist activity. This combination of actions at CNS receptors is thought to rebalance excitatory and inhibitory sexual pathways. The FDA prescribing information describes this mechanism in detail.

Why Insurers Scrutinize the Claim

Because flibanserin carries a REMS requirement and a list price of roughly $880 per month, payers including TRICARE routinely apply prior-authorization (PA) gatekeeping. That scrutiny also reflects the modest average clinical effect seen in trials. In the phase 3 BEGONIA trial (N = 949), women receiving flibanserin 100 mg nightly reported a mean increase of 0.8 satisfying sexual events per month above placebo at 24 weeks, alongside statistically significant reductions in distress scores (P<0.001). BEGONIA full results are indexed at PubMed.

TRICARE Formulary Status for Addyi

TRICARE does not publish a single universal formulary in the way commercial plans do. Coverage is administered through managed-care contractors: Humana Military for the East region and HealthNet Federal Services for the West region, plus the TRICARE Pharmacy Benefits program operated through Express Scripts. Addyi is not listed as a preferred brand on the TRICARE Basic Core Formulary. The Express Scripts TRICARE formulary search tool can confirm current tier placement.

Tier Placement and Cost-Share

Because flibanserin is a non-preferred brand, TRICARE beneficiaries who obtain an approved prescription face the non-preferred brand cost-share structure. At a military treatment facility (MTF) pharmacy, cost-share is typically $0 for formulary items but varies for non-formulary drugs. At a TRICARE-network retail pharmacy, the non-preferred brand copay tier applies. TRICARE pharmacy copay schedules are published by the Defense Health Agency.

Active Duty vs. Retired Beneficiaries

Active-duty servicemembers receive care primarily through MTF pharmacies, where non-formulary drugs may still be dispensed but require additional clinical justification. Retired beneficiaries using TRICARE Select or TRICARE For Life face different cost-share structures. TRICARE benefit comparison details are available at tricare.mil.

Prior Authorization Criteria for Addyi Under TRICARE

TRICARE's PA process for flibanserin typically requires the prescribing clinician to document several specific points. Getting these right the first time reduces the chance of an initial denial.

Diagnosis Documentation

The prescriber must confirm a diagnosis of acquired, generalized HSDD using validated screening tools. The most widely cited instrument in clinical practice is the Female Sexual Distress Scale-Revised (FSDS-R), where a score of 11 or higher on the total scale indicates clinically significant distress. The FSDS-R validation study is available at PubMed. The diagnosis must be documented in the medical record with the ICD-10 code F52.0 (hypoactive sexual desire dysfunction).

Premenopausal Status Confirmation

Flibanserin is FDA-approved only for premenopausal women. TRICARE PA forms typically ask for confirmation of premenopausal status, often supported by a recent FSH level or menstrual history notation. The FDA label explicitly restricts the indication to premenopausal women.

Alcohol and Drug Interaction Counseling

The REMS program mandates that prescribers counsel patients about alcohol avoidance and document that counseling in the chart. The Addyi REMS details are posted at the FDA REMS database. TRICARE reviewers frequently check for this documentation when evaluating a PA request.

Ruling Out Contributory Conditions

Before approving flibanserin, TRICARE may require documentation that the following have been addressed: depression or other mood disorders, relationship distress, thyroid dysfunction, and medications known to suppress libido (such as SSRIs or oral contraceptives). A 2016 review in the Journal of Sexual Medicine summarizes the differential diagnosis of HSDD.

Does TRICARE Require Step Therapy Before Approving Addyi?

Step therapy for flibanserin is not universally required across all TRICARE regions, but it is applied by some contractor medical policy guidelines. When step therapy is required, it typically means the patient must have tried and documented an inadequate response to one or more of the following before flibanserin will be approved.

Common Step-Therapy Requirements

• Psychosexual counseling or sex therapy (usually 8 to 12 sessions with a licensed therapist).
• Evaluation and, where indicated, a trial of thyroid optimization if TSH is abnormal.
• Discontinuation or substitution of libido-suppressing medications if clinically feasible.

The American College of Obstetricians and Gynecologists (ACOG) practice bulletin on sexual dysfunction notes that psychotherapy is an appropriate first-line consideration and that pharmacotherapy is reserved for patients who do not respond adequately.

How to Document Step-Therapy Completion

Progress notes from a licensed therapist, dated prescription records showing a trial of a different approach, and a concise letter of medical necessity from the prescriber all strengthen a PA request where step therapy has been attempted. The letter should state the number of sessions completed, the outcome measure used, and the reason further non-pharmacologic management is not expected to succeed.

How to Submit a Prior Authorization for Addyi Through TRICARE

PA requests for retail pharmacy fills go through Express Scripts, which manages the TRICARE pharmacy benefit under contract. For MTF prescriptions, the MTF pharmacy director or clinical pharmacist handles the non-formulary request internally.

Retail Pharmacy PA Process

1. The prescribing clinician (or their office) calls or logs into the Express Scripts TRICARE PA portal.
2. Submit ICD-10 code F52.0, premenopausal status documentation, REMS counseling note, and any step-therapy completion records.
3. Express Scripts has 72 hours for a standard PA decision and 24 hours for an urgent request. TRICARE pharmacy benefit PA timelines are described at the Defense Health Agency pharmacy site.
4. Approvals are typically valid for 12 months, after which re-authorization is required.

What Triggers an Automatic Denial

Missing REMS documentation, absence of a formal FSDS-R score or equivalent distress documentation, and a postmenopausal diagnosis code are the three most common reasons for immediate denial. Correcting these before resubmission is faster than filing a formal appeal.

How to Appeal a TRICARE Denial of Addyi

A denial is not the end of the road. TRICARE's appeals process has defined statutory timelines that the contractor must follow.

Step 1: Request a Reconsideration

Within 90 days of the denial notice, the beneficiary or prescriber may request a reconsideration from the managed-care contractor (Humana Military or HealthNet Federal Services). Submit additional clinical documentation at this stage, including a detailed letter of medical necessity. The TRICARE appeals process is outlined at tricare.mil.

Step 2: Formal Appeal to TRICARE

If reconsideration is denied, a formal appeal can be filed with the Defense Health Agency (DHA). At this stage, the case is reviewed by a DHA medical officer. The appeal must be filed within 90 days of the reconsideration denial. DHA appeals procedures are described in the TRICARE Policy Manual, Chapter 2.

Step 3: External Independent Review

If the DHA denies the formal appeal, beneficiaries may request an external independent review. This review is conducted by a contractor with no financial interest in the outcome and must be completed within 30 calendar days. The right to external review is grounded in 10 U.S.C. § 1079.

What to Include in Every Appeal

A strong TRICARE appeal for flibanserin includes: a copy of the denial letter, a physician letter of medical necessity signed by the prescribing clinician, peer-reviewed references supporting the clinical necessity of flibanserin specifically (not alternatives), the validated FSDS-R score showing a total of 11 or higher, and documentation that contributory causes have been evaluated. Published HSDD management guidelines from the International Society for the Study of Women's Sexual Health (ISSWSH) can serve as supporting literature.

Can You Use the Addyi Manufacturer Savings Card With TRICARE?

No. Federal law prohibits the use of pharmaceutical manufacturer copay assistance cards, coupons, or savings programs when a federal health plan (including TRICARE, Medicare, or Medicaid) is the payer. This prohibition applies regardless of whether TRICARE is primary or secondary. The Office of Inspector General has issued guidance on this point.

What Flibanserin Costs Out of Pocket

Without insurance, the average retail price of flibanserin 100 mg (30 tablets) is approximately $880 per month. GoodRx and similar discount programs are not manufacturer coupons and are technically usable, but using a discount card voids TRICARE coverage for that fill. A cash-pay prescription processed through a discount program cannot later be resubmitted to TRICARE. Patients facing a denial should pursue the appeal process rather than abandoning insurance coverage.

Clinical Evidence Supporting Medical Necessity Arguments

When building a PA or appeal, citing specific trial data strengthens the case considerably.

BEGONIA Trial

The phase 3 BEGONIA trial (N = 949, 24 weeks) demonstrated that flibanserin 100 mg nightly increased satisfying sexual events by a mean of 0.8 per month more than placebo (P<0.001) and reduced the FSDS-R desire domain score by 13.2 points vs. 9.3 with placebo. BEGONIA is indexed at PubMed.

SNOWDROP and DAISY Trials

The SNOWDROP trial (N = 1,378) and the DAISY trial (N = 1,370) are the two other key phase 3 studies that supported FDA approval. Both showed statistically significant improvements in satisfying sexual events and distress scores over 24 weeks. SNOWDROP and DAISY data appear in the FDA medical review for NDA 022526.

Meta-Analytic Perspective

A 2016 systematic review and meta-analysis of flibanserin trials published in JAMA Internal Medicine (Jaspers et al., N>11,000 across eight trials) found a statistically significant but modest benefit: 0.49 additional satisfying sexual events per month (95% CI 0.32 to 0.67) compared with placebo. That meta-analysis is indexed at PubMed. Acknowledging this modest effect size while emphasizing the individual patient's documented distress score is the most credible framing for a medical necessity letter.

Original HealthRX Decision Framework for Flibanserin PA Under TRICARE

The following four-step framework is used by the HealthRX clinical team when preparing TRICARE PA submissions for flibanserin. It is designed to address the three most common denial triggers (missing REMS documentation, absent distress scoring, and postmenopausal diagnosis) before submission.

Step 1, Confirm eligibility. Verify premenopausal status with FSH <25 mIU/mL or documented regular menses. Record ICD-10 F52.0.

Step 2, Score distress. Administer the FSDS-R at the clinical visit. Document the total score and the desire subdomain score in the chart note. A total score of 11 or higher is the threshold used in the key trials. FSDS-R validation: PubMed.

Step 3, Complete REMS. Confirm the prescriber is REMS-certified. Document alcohol counseling in the visit note with exact language: "Patient counseled on absolute avoidance of alcohol during flibanserin therapy and risks of hypotension and syncope." REMS certification: FDA REMS database.

Step 4, Document step therapy. If the contractor policy requires prior psychosexual therapy, attach dated therapy progress notes or a letter from the treating therapist confirming sessions completed and the clinical outcome. ACOG practice bulletin on female sexual dysfunction supports this sequencing.

Submitting all four components in the initial PA request reduces the back-and-forth with Express Scripts and cuts average PA turnaround time in the HealthRX cohort.

Special Populations and Additional Considerations

TRICARE For Life Beneficiaries

TRICARE For Life (TFL) wraps around Medicare as a secondary payer. Medicare Part D does not cover flibanserin because it lacks an approved indication for a Medicare-eligible population (the drug is only indicated for premenopausal women, and most TFL beneficiaries are age 65 or older). For the rare TFL beneficiary who is premenopausal (under 65 but Medicare-eligible due to disability), flibanserin coverage would go through the TFL pharmacy benefit rather than Medicare Part D, and the same PA process described above applies. Medicare Part D coverage exclusions are described at CMS.gov.

TRICARE Young Adult

TRICARE Young Adult (TYA) enrollees follow the same formulary and PA rules as standard TRICARE Select. Young adult women diagnosed with HSDD who are premenopausal and otherwise eligible may submit a PA request through the same Express Scripts pathway. TYA benefit details are at tricare.mil.

Concurrent SSRI Use

A meaningful number of women with HSDD are also on SSRIs for depression or anxiety. SSRIs are a known cause of acquired HSDD. Before initiating flibanserin, the prescriber should document a clinical assessment of whether the SSRI is contributing to low desire and whether a switch to bupropion (which has a more favorable sexual side-effect profile) is clinically appropriate. A 2022 study in the Journal of Sexual Medicine examined SSRI-associated sexual dysfunction and management options. If SSRI continuation is necessary, the PA letter should explain why discontinuation or substitution is not feasible.

Monitoring After Approval

Once TRICARE approves flibanserin and the prescription is filled, clinical follow-up at 4 and 8 weeks is standard practice. If no improvement in satisfying sexual events or distress scores is observed after 8 weeks of consistent nightly dosing, the FDA label recommends discontinuation. The FDA label states this discontinuation criterion explicitly. Documenting this follow-up also supports re-authorization at the 12-month PA renewal by demonstrating clinical benefit.